Evidence map›Paper›PMID 41618768›Full record

ArticleThe Journal of international medical research2026

From schizophrenia to dementia: Is Cobenfy a potential treatment for behavioral and psychological symptoms of dementia?

Julia C Golden, Kayla S Murphy, Rajesh R Tampi

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Julia C GoldenDepartment of Psychiatry, Brigham and Women's Hospital, USA.ORCID 0009-0007-7114-7084
Kayla S MurphyDepartment of Psychiatry, University of Texas Southwestern Medical Center, USA.
Rajesh R TampiDepartment of Psychiatry, Creighton University, USA.ORCID 0000-0002-9629-2794

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Behavioral and psychological symptoms of dementia significantly impact patient outcomes, caregiver burden, and healthcare costs. Current pharmacologic treatments are limited by efficacy and safety concerns. Cobenfy, a novel combination of xanomeline and trospium chloride, has shown efficacy in schizophrenia and presents a promising alternative for treating behavioral and psychological symptoms of dementia. This editorial explores the potential role of Cobenfy in the management of behavioral and psychological symptoms of dementia. To date, no trials of Cobenfy for behavioral and psychological symptoms of dementia have been completed; however, multiple trials are underway to investigate this medication for psychosis and agitation in Alzheimer's disease. Cobenfy may offer a safer pharmacologic option for behavioral and psychological symptoms of dementia compared with existing treatments. Further research in older adult populations is warranted.

Indexed as

Antipsychotic AgentsBenzilatesDementiaNortropanesSchizophreniaThiadiazolesAlzheimer DiseaseDrug CombinationsHumansAntipsychotic AgentsBenzilatesDrug CombinationsNortropanesThiadiazolestrospium chloridexanomeline, trospium drug combinationagitationAlzheimer’s diseaseDementiatrospium chloridexanomeline

Identifiers

PMID41618768
PMCPMC12861390

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.